1. Home
  2. NUVL vs BTG Comparison

NUVL vs BTG Comparison

Compare NUVL & BTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

HOLD

Current Price

$97.75

Market Cap

8.1B

Sector

Health Care

ML Signal

HOLD

Logo B2Gold Corp

BTG

B2Gold Corp

HOLD

Current Price

$4.85

Market Cap

7.2B

ML Signal

HOLD

Company Overview

Basic Information
Metric
NUVL
BTG
Founded
2017
2006
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Precious Metals
Sector
Health Care
Basic Materials
Exchange
Nasdaq
Nasdaq
Market Cap
8.1B
7.2B
IPO Year
2021
2007

Fundamental Metrics

Financial Performance
Metric
NUVL
BTG
Price
$97.75
$4.85
Analyst Decision
Strong Buy
Buy
Analyst Count
15
2
Target Price
$135.33
$6.00
AVG Volume (30 Days)
436.1K
27.6M
Earning Date
05-27-2026
01-01-0001
Dividend Yield
N/A
1.57%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$34.85
Revenue Next Year
$1,064.25
$23.18
P/E Ratio
N/A
$34.75
Revenue Growth
N/A
N/A
52 Week Low
$55.54
$2.53
52 Week High
$113.02
$6.29

Technical Indicators

Market Signals
Indicator
NUVL
BTG
Relative Strength Index (RSI) 42.01 39.53
Support Level $73.22 $4.74
Resistance Level $107.13 $5.89
Average True Range (ATR) 3.82 0.27
MACD -0.35 -0.11
Stochastic Oscillator 19.08 2.05

Price Performance

Historical Comparison
NUVL
BTG

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

About BTG B2Gold Corp

B2Gold Corp is an international, low-cost, senior gold mining company. It has three operating open-pit gold mines in Mali, Namibia, and the Philippines and numerous exploration projects across four continents. Other assets include the Gramalote and Kiaka gold projects. The company focuses on acquiring and developing interests in mineral properties with a primary focus on gold deposits as gold production forms all its revenue. There is no dependence on a particular purchaser because the gold is sold into various markets. The company's reportable operating segments include its mining operations and development projects, namely Fekola; Masbate; Otjikoto; the Goose Project, and other mineral properties; and corporate and other.

Share on Social Networks: